741 filings
Page 3 of 38
4
5m8eq2y
30 Nov 23
KINETA / CRAIG W. PHILIPS ownership change
5:27pm
4
fmzx onu64fpcc
30 Nov 23
KINETA / Shawn Iadonato ownership change
5:21pm
EFFECT
dwlz6cb bkgrnuyho3
15 Nov 23
Notice of effectiveness
12:15am
424B3
9iv1pg5u0b54wr4
13 Nov 23
Prospectus supplement
5:28pm
UPLOAD
ar0cq7g 1zdlhg
9 Nov 23
Letter from SEC
12:00am
CORRESP
xf11 uz583f4z
9 Nov 23
Correspondence with SEC
12:00am
8-K
mv2iwagt sfjlaoowvxx
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
c5m6h0qnf5 u46r6h5
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
u924x7zz25
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
D
52pni3f8mcu13fo3d6fz
20 Oct 23
$2.89 mm in options / securities to be acquired, 1 investor
1:04pm
8-K
2dc0e3dgah3u8j
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
4
7zptib5rc7k5t30w
12 Oct 23
KINETA / Marion R Foote ownership change
4:25pm
8-K
gaa64of
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
v553jdz5pdkwuni3h3s
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
5kn6ut
4 Oct 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
8:30am
8-K
x1qokx 680nq
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
4
gudt9q
21 Sep 23
KINETA / CRAIG W. PHILIPS ownership change
4:58pm
4
anxcxl psi507r6g9
21 Sep 23
KINETA / Pauline Kenny ownership change
4:57pm